Possible side effects after eractuzumab injection

Elranatamab (Elranatamab), as a new bispecific antibody drug, has been proven to have significant anti-tumor activity during its clinical use in the treatment of relapsed or refractory multiple myeloma. However, as an immunomodulatory biological agent, its side effects cannot be ignored. Especially after injection administration, some patients may experience a series of adverse reactions related to immune responses. These side effects need to be fully understood and prepared for monitoring before use.

One of the most common adverse reactions is cytokine release syndrome (CRS), which is an inflammatory reaction caused by strong activation of the immune system. Patients may experience fever, chills, hypotension, shortness of breath and other symptoms. Although most CRS manifests as mild to moderate, it may progress to severe reactions if not treated in time. Therefore, a hospital observation system is often adopted in the early stage of injection, and preventive drugs such as steroids or tocilizumab are used to control the risk.

In addition, neurotoxic reactions are also worth noting, mainly manifesting as dizziness, drowsiness, confusion, and even epileptic activity. Although the incidence of such side effects is not high, once they occur, the medication should be stopped immediately and symptomatic treatment should be given. Some patients may also experience low blood cell counts, such as neutropenia, thrombocytopenia, etc., leading to reduced immunity or bleeding tendencies, so regular blood monitoring is required.

In terms of skin and mucous membranes, rash, itching, or oral mucosal inflammation are occasionally seen after injection of enantuzumab. These are mostly reversible reactions that can be relieved by local care and anti-inflammatory treatment. In addition, due to systemic activation of the immune system, a very small number of patients may experience immune-mediated adverse events, such as elevated liver enzymes, abnormal thyroid function, etc., and need to cooperate with endocrine and liver function monitoring.

Reference materials:https://www.drugs.com/mtm/elranatamab.html